By Connor Hart

Regeneron Pharmaceuticals said a mid-stage study of its potential obesity treatment found that it could meaningfully preserve muscle mass while enhancing fat loss.

The biotechnology company said Wednesday the combination of semaglutide, a weight-loss drug, and trevogrumab, a drug that preserves muscle mass, could significantly reduce the loss of lean mass associated with semaglutide-induced weight loss.

Results from a recent Phase 2 trial confirmed that about one-third of weight loss induced by semaglutide was due to the loss of lean mass, and that adding trevogrumab could prevent about half of this lean mass loss.

"These encouraging early data, with positive trends in lipid parameters, warrant further studies to confirm the potential of trevogrumab's role in preserving lean muscle mass during weight loss," said Julio Rosenstock, director of the Dallas Diabetes Research Center at Medical City, and a clinical professor of medicine at the University of Texas Southwestern Medical Center, Dallas.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

September 17, 2025 10:15 ET (14:15 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.